Recommendations for clinical trial evaluation of acute stroke therapies

Stroke

Volumn 32, Issue 7, 2001, Pages 1598-1606

  Albers, G W ^a   Bogousslavsky, J ^a   Bozik, M A ^a   Brass, L M ^a   Broderick, J P ^a   Fisher, M ^a   Goldstein, L B ^a   Salazar Grueso, E ^a   Zivin, J A ^a  

^a University of Massachusetts   (United States)

Author keywords

Clinical trials; Stroke, acute; Therapy

Indexed keywords

FIBRINOLYTIC AGENT;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HUMAN; NEUROPROTECTION; PRIORITY JOURNAL; STROKE;

EID: 0034943173     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.32.7.1598     Document Type: Article

References (43)

1. Tissue plasminogen activator for acute ischemic stroke
2. Intra-arterial prourokinase for acute ischemic stroke
3. Intravenous ancrod for treatment of acute ischemic stroke: The STAT study: A randomized controlled trial. Stroke Treatment with Ancrod Trial
4. Recommendations for standards regarding preclinical neuroprotective restorative drugs
5. Clinical trials with neuroprotective drugs in acute ischemic stroke: Are we doing the right thing?
6. What are surrogate outcome measures and why do they fail in clinical research?
7. Acute clinical trials: An expression of concern
8. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)
9. Are more complex study designs needed for future acute stroke trials?
10. Neuropathological endpoints in experimental stroke pharmacotherapy: The importance of both early and late evaluation
11. Recent progress in drug treatment for acute stroke
12. The effect of intravenous rt-PA on ischemic lesion volume as measured by computed tomography
13. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA Stroke Trial
14. Applications of diffusion-perfusion magnetic resonance imaging in acute stroke
15. Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI
16. Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis
17. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis
18. PROACT: A phase 2 randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke
19. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
20. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS trial: A randomized controlled trial
21. Neuroprotection of acute ischemic stroke: Where are we?
22. Anoxic and ischemic injury of myelinated axons in CNS white matter: From mechanistic concepts to therapeutics
23. Diffusion-weighted MRI in acute subcortical infarcts
24. Ischemic core and penumbra in human stroke
25. Computed tomographic angiography: Historical perspective and new state of the art multi-detector row helical computed tomography
26. Ultrasound criteria for middle cerebral artery recanalization and angiographic correlation
27. Characterizing the target of acute stroke treatment
28. Baseline NIH stroke scale score strongly predicts outcome after stroke: A report of the trial of Org 10172 in acute stroke treatment (TOAST)
29. For the citicoline acute ischemic stroke study group: A randomized efficacy trial of citicoline in patients with acute ischemic stroke
30. Interobserver agreement for the assessment of handicap in stroke patients
31. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: A randomised controlled trial
32. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial
33. Play the winner for phase II/III clinical trials
34. Adaptive design improvements in the continual reassessment method for phase I studies
35. Combination therapy protects ischemic brain in rats: A glutamate antagonist plus a gamma-aminobutyric acid agonist
36. Combination chemotherapy extends the therapeutic window to 60 minutes after stroke
37. Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke
38. Early recanalization in acute ischaemic stroke saves tissue at risk defied by MRI
39. Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy
40. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging
41. Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat
42. Combination therapy stroke trial: rt-PA +/- lubeluzole
43. Safety and efficacy of combined clomethiazole and tPA for acute stroke: CLASS-T: A pilot study